There are many common and often serious errors made during the establishment and maintenance of a radiotherapy program that can be identified through independent peer review. Physicists should be cautious, particularly in areas highlighted herein that show a tendency for errors.
Material and Methods:
In an IRB approved study, 26 patients with gynecological cancer scheduled for definitive (9) or postoperative (17) radiotherapy were scanned in prone and supine position at the same day. The primary CTV (proximal part of the vagina and intact cervix-uterus or vaginal cuff with paravaginal soft tissue), nodal CTV, bladder, bowel cavity, and rectum were delineated on both scans. Nine PTVs were created, each with a different margin for the primary and nodal CTV (Table 1) . Pareto optimal IMRT plans with 20 equi-angular beams to be delivered with dMLC were generated using our in-house system for automated treatment planning. Previously, we demonstrated that 20 beam IMRT is superior to dual arc VMAT. For all primary/nodal margin combinations supine and prone plans were compared considering OAR dose-volume parameters, giving highest priority to bowel cavity. P-values < 0.05 were considered significant. To determine the sensitivity of the dosimetric difference to the needed margin we not only compared supine to prone treatment plans with similar margins, but also compared supine to prone plans for which the supine plans had a smaller margin than for prone. In that way, we assessed the scenario that in prone position a larger margin around the nodal CTV is needed due to increased patient setup variations. Figure 1 illustrates the comparison between supine and prone position in terms of V45Gy of the bowel cavity for all patients and margins. Prone setup was significantly superior for large margins, but not for the three smallest margin combinations, i.e. 5/5mm, 5/7mm, and 10/5mm (primary/nodal margin around CTV). The rectum Dmean was significantly lower in prone setup: 2.9 Gy ± 0.4 averaged over all margins and patients, while the bladder Dmean was lower in supine setup: 2.5 Gy ± 0.3. The significant advantage for prone setup was not present if prone setup needed a larger margin than supine. In that case the V45Gy of the bowel cavity was on average 27 cc lower in supine setup.
Results:

Material and Methods:
Treatment plans using 6 MV FFF VMAT (1400 MU/min) were created for three liver metastases (TrueBeam and Eclipse, Varian Medical Systems). The prescribed dose was 36 Gy in 3 fractions. The arcs were divided into sub-beams (one for every two control points) using an in-house developed software and the isocenter was shifted for every sub-beam to simulate sinusoidal motion in the superior-inferior direction. The sub-beams were calculated in Eclipse, generating a 4D dose distribution including effects of motion. For each treatment plan, combinations of three different motion amplitudes (5, 15 and 25 mm peak-to-peak) and periods (3, 5 and 7 s) were simulated. To separate the interplay effect from dose blurring, the original 3D dose distribution was convolved with the motion pattern and subtracted from the simulated 4D dose distribution, and the resulting D1%-D99% was calculated for the ITV. To verify the method, simulated treatment plans were delivered in developer mode to the Delta4 phantom positioned on Hexamotion (ScandiDos), which was either static or moving sinusoidally with a peak-to-peak distance of 15 mm and a period time of 5 seconds during irradiation. The measured and simulated dose distributions were compared using gamma analysis (2%/2 mm local dose, cut-off dose 10%) in the Delta4 software. To synchronize the isocenter shifts in the simulations with the motion during the measurements, kV images were acquired asynchronously during beam delivery.
Results: Gamma analysis show good agreement between the simulated 4D dose distribution and the dynamic measurement, comparable to the original 3D dose distribution and the static measurement (table 1). The impact of the interplay effects, expressed as D1%-D99%, varies considerably between targets as well as the combination of tumour amplitude and period time (figure 1), with a maximum difference in D1%-D99% compared to no motion of 2.8 Gy (target 2, 25 mm, 7s).
Conclusion:
A method to calculate the absorbed dose to moving tumours was developed and verified by measurements. Using this method, it was shown that large interplay effects may occur, with no obvious relation to the motion pattern. Therefore, caution should be taken before using FFF VMAT for moving liver tumours without using motion management techniques.
OC-0463
Improving treatment plan quality of SBRT lung tumors using a new gradient index E. Van Purpose or Objective: In order to assess treatment plan quality a good strategy is to compare plan quality indices for similar patients treated previously. For SBRT treatments the dose gradient is strongly associated with plan quality. Our objective is to introduce and show the merits of a gradient index for (lung) SBRT treatment plans that is, in contrast with existing indices, usable for multiple tumors and is readily interpretable.
Material and Methods:
Our gradient index is defined as the relative dose-gradient averaged over the voxels in the first centimeter around the PTV. When a patient has multiple tumors, voxels closer to other tumors are excluded from the average, see inset of Fig. 1 . For 100 tumors of lung SBRT patients treated in our clinic we calculated the proposed gradient index as well as other possible quality indices, such as conformity (ratio of volume receiving prescribed dose to volume of PTV) and inhomogeneity (ratio of max and prescribed dose). In addition, we listed geometric parameters such as volume, position in the lung, and distance to various OARs of the GTVs. We establish the mutual correlations of the plan quality indicators and dependencies on geometric factors. To test whether the suggested parameter indeed measures quality we select five low-scoring patients, including a patient with multiple tumors, and try to improve the treatment plans with respect to the suggested gradient index without compromising other constraints.
Results: For peripheral tumors the average relative dosegradient in the first cm from the edge of the PTV is 5.6 ± 0.6 %/mm, shown in Fig. 1 . It is independent of volume, position in the lung and does not correlate with the conformity index, in contrast to other gradient indices. For five low-scoring patients we could improve the dose-gradient on average by 0.5 %/mm without compromising target coverage and conformity. By increasing the gradient in the first centimeter around the PTV the average dose in most OARs was reduced, with an 8% reduction in average dose to the whole patient excluding PTV and an 6% reduction to average dose to healthy lung tissue.
